The Boston-based biotech is axing Phase II plans for its only clinical-stage asset, in a bid to maximise shareholder value.

Mounjaro generated sales of $6.5bn in Q3 2025, up 109% from the same period in 2024. Zepbound exhibited even higher growth – ...

Helex has raised $3.5m in a seed funding round spearheaded by pi Ventures to advance non-viral gene therapies for kidney ...

As healthcare systems work towards new sustainability goals, medical textiles have become a key focus for innovation.

Swiss-based Debiopharm has formed a research partnership with South Korea-based AI drug discovery company NetTargets.

The FDA's draft guidance is supposed to cut the cost and time-associated burden of biosimilar development, despite a mixed ...

Eli Lilly will invest over $1.2bn into its manufacturing site in Puerto Rico, as it aims to assemble a robust supply chain ...

Novartis has signed an agreement for the acquisition of all the outstanding shares of US-based Avidity Biosciences.

Epioxa by Glaukos Corp received US Food and Drug Administration (FDA) approval on 20 October as the first and only ...

Eli Lilly and NVIDIA will build a new supercomputer to accelerate drug discovery and shorten development cycles.

GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...